Fractal Analytics Q4 Profit More Than Doubles to ₹116 Cr; Becomes Debt-Free

TECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Fractal Analytics Q4 Profit More Than Doubles to ₹116 Cr; Becomes Debt-Free
Overview

Fractal Analytics closed its fiscal year ending March 31, 2026, with strong results. The AI firm's profit after tax more than doubled to ₹116 crore, up from ₹55.5 crore a year ago. Revenue grew 17% to ₹886 crore, led by 82% growth in its Healthcare and Life Sciences segment. Fractal also announced it is now debt-free after repaying long-term debt with IPO funds.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Strong Segment Performance

Growth was driven by the Healthcare and Life Sciences (HLS) segment, which grew 82% year-over-year in Q4 and 66% for the full fiscal year. The Banking, Financial Services, and Insurance (BFSI) segment also added positively, with 32% growth for the entire year. These sector gains contributed to the company's overall financial increase.

Geographic Expansion and Revenue Growth

Consolidated revenue from operations rose 17% to ₹886 crore in the quarter, up from ₹757.5 crore in the same period last year. The Americas, representing 68% of Fractal's revenue, grew 17% year-over-year. Europe, which accounts for 18% of total revenue, saw 24% growth.

Debt-Free Status Achieved

Fractal Analytics ended the fiscal year with ₹2,052 crore in cash, including ₹957 crore from IPO proceeds. These funds were used in April to fully repay long-term debt. The company now operates with no outstanding debt.

Key Client Wins Bolster Outlook

Looking ahead, Fractal Analytics secured a new partnership with a top five US life sciences company. The agreement covers delivery of two AI companions for commercial pharma marketing and field excellence, showing strong demand for its AI solutions.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.